Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Vedanta Biosciences starts Phase II VE303 trial to treat rCDI

VE303 is being developed as a treatment for clostridium difficile infection. Credit: Sanofi Pasteur.

  • Vedanta Biosciences

Go Top